AAM Code of Business Ethics | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard interviews pharmaceutical industry veteran Bob Billings

AAM Code of Business Ethics

Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and biosimilar medicines. Our companies produce and distribute the medicines that make up approximately 90% of all prescriptions filled in the United States – but at just 26% of total prescription drug spending. We serve as a key pillar in our national healthcare system. Our work includes promoting marketplace competition and supporting strategic enhancements to the Food and Drug Administration’s (FDA) generic drug and biosimilar approval process. We do this for one purpose: to put affordable medicines within the reach of patients who need them. Every dollar saved at the pharmacy counter is a dollar that patients can spend on life’s essentials and other pursuits — or put away for future use. We help patients live better lives, and we do so in a way that saves precious resources for patients, taxpayers, and our economy.

Today we introduce the Association for Accessible Medicines (AAM) Code of Business Ethics. The practices discussed in this Code represent behaviors that our companies have been demonstrating for many years. And yet, it is incumbent on us to declare to our patients and customers the values upon which our industry is based, and the ethical and business standards upon which we are committed to operating with other members of the healthcare ecosystem.

The Association of Accessible Medicines (AAM) Code of Business Ethics is applicable to the operation of generic drug and biosimilar companies who adopt the Code in the United States and interactions with United States healthcare professionals. AAM’s Board of Directors has approved this Code. 

View AAM Code of Ethics

AAM White Paper First Generics

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.